47 related articles for article (PubMed ID: 20664355)
1. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.
Guislain A; Gadiot J; Kaiser A; Jordanova ES; Broeks A; Sanders J; van Boven H; de Gruijl TD; Haanen JB; Bex A; Blank CU
Cancer Immunol Immunother; 2015 Oct; 64(10):1241-50. PubMed ID: 26105626
[TBL] [Abstract][Full Text] [Related]
3. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival.
Griffiths RW; Elkord E; Gilham DE; Ramani V; Clarke N; Stern PL; Hawkins RE
Cancer Immunol Immunother; 2007 Nov; 56(11):1743-53. PubMed ID: 17487490
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma.
Hermann GG; Geertsen PF; von der Maase H; Zeuthen J
Cancer Immunol Immunother; 1991; 34(2):111-4. PubMed ID: 1760814
[TBL] [Abstract][Full Text] [Related]
5. High-dose continuous venous infusion of interleukin-2: influence of dose and infusion rate on tumoricidal function and lymphocyte subsets.
Mertens WC; Banerjee D; al-Mutter N; Stitt L; Bramwell VH; Lala PK
Cancer Immunol Immunother; 1995 Nov; 41(5):271-9. PubMed ID: 8536272
[TBL] [Abstract][Full Text] [Related]
6. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcome.
Foureau DM; Amin A; White RL; Anderson W; Jones CP; Sarantou T; McKillop IH; Salo JC
Cancer Immunol Immunother; 2014 Dec; 63(12):1329-40. PubMed ID: 25205170
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
Thistlethwaite FC; Elkord E; Griffiths RW; Burt DJ; Shablak AM; Campbell JD; Gilham DE; Austin EB; Stern PL; Hawkins RE
Cancer Immunol Immunother; 2008 May; 57(5):623-34. PubMed ID: 17899077
[TBL] [Abstract][Full Text] [Related]
8. IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
Falkensammer C; Jöhrer K; Gander H; Ramoner R; Putz T; Rahm A; Greil R; Bartsch G; Thurnher M
Cancer Immunol Immunother; 2006 Oct; 55(10):1228-37. PubMed ID: 16810557
[TBL] [Abstract][Full Text] [Related]
9. The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.
Beebe KD; Eisner JR; Guo J; Shibata Y; Davison JM; Uronis J; Farhangfar C; Farhangfar F; Mooney J; Milburn MV; White RL; Amin A; Milla ME; Foureau DM
J Immunol; 2024 May; ():. PubMed ID: 38767437
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of Aggregated Proteins by the ClpB/DnaK Bi-Chaperone System.
Zolkiewski M; Chesnokova LS; Witt SN
Curr Protoc Protein Sci; 2016 Feb; 83():28.10.1-28.10.18. PubMed ID: 26836408
[TBL] [Abstract][Full Text] [Related]
11. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
Grünwald V
Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
[TBL] [Abstract][Full Text] [Related]
12. Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.
Mahdi HS; Woodall-Jappe M; Singh P; Czuczman MS
Front Immunol; 2023; 14():1268979. PubMed ID: 38022532
[TBL] [Abstract][Full Text] [Related]
13. So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.
Kleinman AJ; Pandrea I; Apetrei C
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062339
[TBL] [Abstract][Full Text] [Related]
14. Nonhuman Primate Testing of the Impact of Different Regulatory T Cell Depletion Strategies on Reactivation and Clearance of Latent Simian Immunodeficiency Virus.
Sivanandham R; Kleinman AJ; Sette P; Brocca-Cofano E; Kilapandal Venkatraman SM; Policicchio BB; He T; Xu C; Swarthout J; Wang Z; Pandrea I; Apetrei C
J Virol; 2020 Sep; 94(19):. PubMed ID: 32669326
[TBL] [Abstract][Full Text] [Related]
15. Regulatory T Cells As Potential Targets for HIV Cure Research.
Kleinman AJ; Sivanandham R; Pandrea I; Chougnet CA; Apetrei C
Front Immunol; 2018; 9():734. PubMed ID: 29706961
[TBL] [Abstract][Full Text] [Related]
16. Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
Gupta S; Cheung L; Pokkali S; Winglee K; Guo H; Murphy JR; Bishai WR
J Infect Dis; 2017 Jun; 215(12):1883-1887. PubMed ID: 28863467
[TBL] [Abstract][Full Text] [Related]
17. The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.
Shi H; Qi X; Ma B; Cao Y; Wang L; Sun L; Niu H
Chin J Cancer Res; 2015 Apr; 27(2):128-37. PubMed ID: 25937774
[TBL] [Abstract][Full Text] [Related]
18. Rational combinations of immunotherapeutics that target discrete pathways.
Spranger S; Gajewski T
J Immunother Cancer; 2013; 1():16. PubMed ID: 24829752
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Monk P; Lam E; Mortazavi A; Kendra K; Lesinski GB; Mace TA; Geyer S; Carson WE; Tahiri S; Bhinder A; Clinton SK; Olencki T
J Immunother; 2014 Apr; 37(3):180-6. PubMed ID: 24598448
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials.
Malik L; Parsons H; Mahalingam D; Ehler B; Goros M; Mejia A; Brenner A; Sarantopoulos J
Clin Genitourin Cancer; 2014 Oct; 12(5):359-65. PubMed ID: 24582088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
